Kimberly P. Cockerham, MD – FDA 483, Jun 3, 2026

An FDA inspection of Kimberly P. Cockerham, MD in Wildwood, FL, revealed significant deviations in the conduct of a clinical investigation. The firm failed to adhere to the signed statement of investigator and investigational plan, including administering investigational product to a subject who met exclusion criteria and after unreported temperature excursions. Additionally, sponsor-provided visual acuity worksheets were not utilized for all randomized subjects.